Biotech stocks posted losses for the third straight week, as the sector reacted to broader market weakness and announcements out of the 2022 JPMorgan Healthcare conference. Swiss biotech Molecular Partners AG was among the best-performing stocks in the past week following the release of positive Phase 2 data for partnered COVID-19 antiviral treatment. Ahead of the fourth-quarter reporting season, preannouncements continued to dominate biotech news. The week also witnessed the debut of Hillstream Biopharma Inc. following its initial public offering, which raised $15 million in gross proceeds for the oncology-focused company. Here are the key catalysts that could move stocks in the unfolding week: Conferences Winter Clinical Dermatology Conference: Jan. 14–19, in Koloa, Hawaii. American Society of Clinical Oncology, or ASCO, Gastrointestinal Cancers Symposium: Jan. 20–22 (hybrid format, in San Francisco, California, and virtual). Société Francophone du Nerf Périphérique, or SFNP, Annual Meeting: Jan. 21–22, in Paris, France. Clinical Data …